| 1471 |
National Cancer Institute |
Html |
en |
Small Intestine Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of small intestine cancer. |
| illustrations | 0.418999 |
| duodenum. | 0.42103 |
| PDQ cancer information | 0.903829 |
| resectable leiomyosarcoma | 0.536755 |
| PDQ information | 0.645092 |
| Small intestine carcinomas | 0.711426 |
| multiple sites | 0.521204 |
| scientific images | 0.511301 |
| malignant lesions | 0.542214 |
| text | 0.419438 |
| cancer information summary | 0.765692 |
| National Institutes | 0.515005 |
| sentence | 0.423056 |
| breast cancer prevention | 0.606867 |
| author | 0.434223 |
| NCI’s PDQ | 0.679179 |
| PDQ Adult Treatment | 0.75546 |
| adenocarcinomas | 0.421075 |
| NCI PDQ cancer | 0.783554 |
| carcinoid tumors | 0.53815 |
| small intestine | 0.82655 |
| jejunum | 0.420595 |
| ileum | 0.420633 |
| relates | 0.424246 |
| resectable adenocarcinoma | 0.544916 |
|
| 5-year survival rate | 0.903147 |
| common primary sarcoma | 0.632045 |
| content | 0.419494 |
| predominant modality | 0.550555 |
| literature | 0.41999 |
| overall 5-year survival | 0.674093 |
| National Cancer Institute | 0.792644 |
| trademark | 0.418975 |
| Editorial Board | 0.520308 |
| ability | 0.4195 |
| PDQ documents | 0.647487 |
| primary malignant tumors | 0.647543 |
| owner | 0.419281 |
| Visuals Online | 0.515575 |
| entirety | 0.426542 |
| Health | 0.419895 |
| cancer-related images | 0.526463 |
| permission | 0.44717 |
| NIH | 0.422847 |
| gastrointestinal malignancies | 0.551608 |
| resection | 0.436749 |
| duodenum | 0.432045 |
| policy statement | 0.518223 |
| independent review | 0.515819 |
|
CLICK HERE |
| 1485 |
National Cancer Institute |
Html |
en |
Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of intraocular (eye) melanoma. |
| uveal melanoma | 0.68476 |
| Medium Tumor Trial | 0.539127 |
| charged-particle ebrt | 0.585479 |
| local tumor regrowth | 0.547533 |
| 125I brachytherapy | 0.543775 |
| uveal melanomas | 0.962507 |
| Option Overview section | 0.565872 |
| local tumor recurrence. | 0.544248 |
| posterior uveal melanomas | 0.679007 |
| plaque radiation therapy | 0.595583 |
| tumor regression rates | 0.537853 |
| uveal tract melanomas | 0.717461 |
| late local radiation | 0.532096 |
| ocular melanoma | 0.519667 |
| histopathologically confirmed melanoma | 0.546989 |
| large choroidal tumors | 0.551303 |
| small melanomas | 0.610711 |
| brachytherapy | 0.555626 |
| all-cause mortality rates | 0.515468 |
| U.S. incidence rates | 0.52364 |
| local control rate | 0.579941 |
| melanoma metastasis-specific survival | 0.54531 |
| prominent tumor vascularity | 0.525035 |
| posterior melanomas | 0.676788 |
|
| large uveal melanomas | 0.659428 |
| patients | 0.552792 |
| visual acuity | 0.646161 |
| optic disc | 0.638287 |
| ciliary body | 0.761795 |
| small choroidal melanoma | 0.601669 |
| ciliary body melanoma | 0.589002 |
| medium-sized choroidal tumors | 0.551291 |
| relatively good outcomes | 0.576295 |
| tumors | 0.574964 |
| Treatment Option Overview | 0.566892 |
| tumor growth warrants | 0.54471 |
| posterior uveal tract | 0.542964 |
| tumor | 0.654818 |
| unequivocal tumor growth | 0.619495 |
| anterior ciliary body | 0.517737 |
| radiation therapy | 0.658453 |
| local tumor control | 0.613746 |
| ocular melanomas | 0.634519 |
| typical choroidal melanoma | 0.592701 |
| statistically significant differences | 0.571591 |
| small choroidal melanomas | 0.778268 |
| iris melanomas | 0.919191 |
|
CLICK HERE |
| 1551 |
National Cancer Institute |
Html |
null |
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders. |
|
|
CLICK HERE |
| 1567 |
National Cancer Institute |
Html |
en |
Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of metastatic squamous neck cancer with occult primary. |
| cancer treatment | 0.331255 |
| neck muscles | 0.258524 |
| cancer spreads | 0.287607 |
| metastatic cancer | 0.293108 |
| malignant tumor cells | 0.281382 |
| body | 0.321816 |
| PDQ cancer information | 0.347021 |
| squamous cells | 0.294186 |
| clinical trial search | 0.272504 |
| external radiation treatment | 0.262886 |
| clinical trials | 0.659393 |
| cancer information summary | 0.31748 |
| clinical trial | 0.463543 |
| squamous cell cancer | 0.363064 |
| breast cancer prevention | 0.264993 |
| radical neck dissection | 0.322726 |
| patients | 0.300058 |
| earlier clinical trials | 0.261657 |
| treatment clinical trial | 0.277097 |
| PDQ Adult Treatment | 0.268031 |
| different types | 0.294996 |
| NCI PDQ cancer | 0.286254 |
| tests | 0.272201 |
| radiation therapy | 0.490196 |
| Treatment Editorial Board | 0.283384 |
|
| lung cancer cells | 0.288937 |
| currently used treatment | 0.262475 |
| metastatic squamous neck | 0.988686 |
| treatment | 0.481959 |
| Occult Primary Treatment | 0.275159 |
| new cancer treatments | 0.27464 |
| cancer cells | 0.387801 |
| Cancer Information Service | 0.273937 |
| PDQ Metastatic Squamous | 0.312989 |
| Hyperfractionated radiation therapy | 0.272771 |
| treatment clinical trials | 0.300592 |
| squamous neck cancer | 0.954253 |
| National Cancer Institute | 0.34026 |
| occult primary | 0.527765 |
| new treatment | 0.321855 |
| new treatments | 0.258619 |
| Cancer Care page | 0.264657 |
| primary tumor | 0.396235 |
| cancer research process | 0.267043 |
| cancer clinical trials | 0.302055 |
| treatment options | 0.305059 |
| cancer information summaries | 0.272694 |
| comprehensive cancer information | 0.272807 |
| occult primary tumor | 0.271623 |
|
CLICK HERE |
| 1656 |
National Cancer Institute |
Html |
null |
Last Days of Life (PDQ®)–Health Professional Version |
Expert-reviewed information summary about care during the last days to last hours of life, including common symptoms, ethical dilemmas that may arise, and the role of the oncologist in caring for patients and their families during this time. |
|
|
CLICK HERE |
| 1752 |
National Cancer Institute |
Html |
en |
Common Moles, Dysplastic Nevi, and Risk of Melanoma |
A fact sheet about moles and how some moles may be related to melanoma, the most serious type of skin cancer. Includes photos of differences between moles and cancer. |
| skin cancer | 0.396204 |
| new pencil eraser | 0.340631 |
| new mole | 0.324515 |
| people—have common moles | 0.296925 |
| areas | 0.255107 |
| Cancer Statistics Review | 0.258106 |
| skin surface | 0.252994 |
| American Cancer Society | 0.291862 |
| dysplastic nevi | 0.760688 |
| ABCDE features | 0.255948 |
| shape | 0.300226 |
| normal moles | 0.26535 |
| melanoma | 0.905882 |
| new moles | 0.27436 |
| distinct edge | 0.298497 |
| UV radiation | 0.254044 |
| mole look | 0.348624 |
| early melanoma | 0.368768 |
| color changes | 0.261127 |
| following changes | 0.256625 |
| moderately increased chance | 0.26864 |
| dysplastic nevus | 0.99874 |
| dark skin | 0.328273 |
| skin damage | 0.265216 |
|
| new colored area | 0.350978 |
| mole changes | 0.343324 |
| skin | 0.706105 |
| people—develop melanoma | 0.334635 |
| cancer cells | 0.262185 |
| sun | 0.303017 |
| atypical mole | 0.288433 |
| National Cancer Institute | 0.258053 |
| frequent skin exam | 0.273598 |
| common moles | 0.677867 |
| chance | 0.337967 |
| greater chance | 0.265511 |
| American adults—about | 0.256684 |
| surface texture | 0.317122 |
| Evolving. The mole | 0.285916 |
| people | 0.632361 |
| doctor | 0.289469 |
| normal skin tone | 0.268972 |
| family history | 0.256672 |
| early melanoma detection | 0.355222 |
| unusual mole | 0.314622 |
| common mole | 0.732427 |
| common mole look | 0.339723 |
| fair skin | 0.271925 |
|
CLICK HERE |
| 2032 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de próstata (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de próstata. |
| or watchful waiting | 0.527761 |
| Prostate Cancer Group-4 | 0.536467 |
| Koyama T | 0.514342 |
| estudio erspc | 0.525762 |
| Sin embargo | 0.633101 |
| Resnick MJ | 0.514745 |
| paÃses cuáles factores | 0.523397 |
| detección versus | 0.572904 |
| Holmberg L | 0.514356 |
| ensayo plco | 0.516954 |
| Swedish Cancer Registry | 0.524495 |
| Ahmed HU | 0.514521 |
| jurisdicciones europeas colaboradoras | 0.519184 |
| Preventive Services Task | 0.58607 |
| Ovarian Cancer Screening | 0.580102 |
| consiguiente tratamiento | 0.524752 |
| Croswell JM | 0.515275 |
| estudio prostate testing | 0.532458 |
| Estados Unidos | 0.630717 |
| centro göteborg | 0.570246 |
| siguientes tasas | 0.517703 |
| Prostate Cancer Prevention | 0.525333 |
| PSA rutinarias | 0.626469 |
| FJ Jr | 0.514192 |
| evolución natural benigna | 0.523168 |
|
| centro sueco göteborg | 0.523946 |
| trascendencia clÃnica | 0.542862 |
| Lancet Oncol | 0.516366 |
| Eur Urol | 0.51628 |
| End Results | 0.514418 |
| Loeb S | 0.514034 |
| Scandinavian Prostate Cancer | 0.583772 |
| seguimiento diagnóstico | 0.518794 |
| Gen Intern Med | 0.526679 |
| lesiones prostáticas benignas | 0.525347 |
| radical prostatectomy | 0.520653 |
| PaÃses Bajos | 0.556513 |
| Fan KH | 0.51463 |
| edad promedio | 0.515679 |
| Chou R | 0.514768 |
| PDQ Tratamiento | 0.51809 |
| European Randomized Study | 0.573324 |
| Intern Med | 0.549412 |
| Steineck G | 0.514536 |
| Services Task Force | 0.584434 |
| prostate cancer | 0.738954 |
| datos probatorios | 0.915311 |
| Prostate Intervention Versus | 0.524636 |
| Cancer Screening Trial | 0.580497 |
|
CLICK HERE |
| 16257 |
National Cancer Institute |
Html |
es |
Prevención |
La investigación del NCI de prevención va desde identificación de factores ambientales y de estilos de vida que influyen en el riesgo de cáncer hasta la biología de la formación del cáncer y la evaluación para diseminar intervenciones de prevención. |
| próxima generación | 0.432035 |
| Mejor reducción | 0.436692 |
| Investigación Nacional Colaborativa | 0.455747 |
| Investigación Oncológica | 0.43883 |
| Nuevos planteamientos | 0.440499 |
| investigación sustancias | 0.43567 |
| Estudio Vida Familiar | 0.45233 |
| Estados Unidos | 0.908876 |
| numerosos factores | 0.443836 |
| cabo estudios | 0.446295 |
| Cáncer apoya programas | 0.610288 |
|
| cánceres más | 0.43473 |
| numerosos estudios | 0.443241 |
| posibles terapias | 0.437443 |
| Pre-Cancer Atlas | 0.437082 |
| el uso | 0.430938 |
| inmensa complejidad | 0.437794 |
| amplio rango | 0.43275 |
| prevención del cáncer del nci | 0.509541 |
| creación de vacunas | 0.467866 |
| prueba formas | 0.434098 |
| Estados Unidos gastarán | 0.466237 |
|
CLICK HERE |
| 16258 |
National Cancer Institute |
Html |
es |
Exámenes de detección y detección temprana |
El NCI apoya y dirige investigación sobre exámenes de detección y detección temprana de cáncer, incluyendo estudios para formular y validar marcadores biológicos. |
| Estados Unidos. | 0.305194 |
| cabo extensión | 0.305776 |
| Investigación Oncológica | 0.305832 |
| Mejor cuantificación | 0.307132 |
| amplia variedad | 0.306584 |
| Estados Unidos | 0.358649 |
| causarán sÃntomas | 0.306983 |
| cáncer colorrectal | 0.434511 |
| cabo análisis | 0.306294 |
| memorable estudio nacional | 0.309583 |
|
| sobretratamiento—el diagnóstico | 0.307579 |
| socioeconómicos especÃficos—que | 0.307995 |
| gente—con frecuencia | 0.307545 |
| cabo el NCI | 0.307119 |
| Mejor detección | 0.335532 |
| factores genéticos causantes | 0.312309 |
| El Programa Nacional Comunitario | 0.309532 |
| Nuevas tecnologÃas | 0.306404 |
| detección temprana | 0.979153 |
|
CLICK HERE |
| 16648 |
National Cancer Institute |
Html |
en |
Track 3: Oncology Product Research and Review for Postdoctoral Research Fellows |
NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program. |
| FDA medical product | 0.724157 |
| pharmacology/toxicology branch | 0.567867 |
| regulatory research | 0.567201 |
| manufacturing processes | 0.657075 |
| reviewer training | 0.533228 |
| FDA scientific review | 0.647979 |
| regulatory requirements | 0.555708 |
| regulatory meetings | 0.534128 |
| Medical Center Dr | 0.604857 |
| fellows | 0.948854 |
| product-related research | 0.563223 |
| molecular targeted therapy | 0.645977 |
| translational research | 0.550405 |
| manufacturing control | 0.548537 |
| research goals | 0.538726 |
| post-marketing surveillance | 0.528754 |
| quality control | 0.651731 |
| Regulatory Review Fellowships | 0.633391 |
| branch chief | 0.620999 |
| research activities | 0.549015 |
| pharmacology/toxicology reviews | 0.559001 |
| particular product division | 0.677124 |
| FDA Centers | 0.6466 |
| product standards | 0.562937 |
| quality assurance | 0.652186 |
|
| Review list | 0.528745 |
| training program | 0.540221 |
| various training activities | 0.644892 |
| relevant federal statutes | 0.651561 |
| formal training | 0.557556 |
| earliest start date | 0.598748 |
| critical ethical issues | 0.628449 |
| medical product development | 0.721681 |
| product research | 0.592749 |
| clinical trial design | 0.65091 |
| postdoctoral training | 0.552346 |
| product development | 0.822368 |
| regulatory presentations | 0.533763 |
| human research subjects | 0.664846 |
| guidance document development | 0.635078 |
| regulatory files | 0.555901 |
| principal investigators | 0.629995 |
| approval process | 0.53653 |
| NCI-FDA Research | 0.537698 |
| program time frame | 0.62474 |
| division director | 0.626349 |
| supplemental training | 0.540819 |
| regulatory experience | 0.537743 |
| cancer biology | 0.538989 |
|
CLICK HERE |